Relypsa Inc. (NASDAQ:RLYP) has earned an average recommendation of “Hold” from the fifteen ratings firms that are currently covering the stock. Twelve equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $32.02.

Several equities research analysts recently issued reports on the stock. Vetr cut shares of Relypsa from a “buy” rating to a “hold” rating and set a $31.16 price objective for the company. in a research report on Monday, September 19th. BTIG Research lowered shares of Relypsa from a “buy” rating to a “neutral” rating in a research note on Thursday, September 1st. Wedbush lowered shares of Relypsa from an “outperform” rating to a “neutral” rating and set a $32.00 target price for the company. in a research note on Thursday, September 1st. Stifel Nicolaus lowered shares of Relypsa from a “buy” rating to a “hold” rating and set a $32.00 target price for the company. in a research note on Monday, August 22nd. Finally, Mizuho reaffirmed a “neutral” rating and set a $32.00 target price on shares of Relypsa in a research note on Saturday, August 13th.

A number of hedge funds and other institutional investors have recently modified their holdings of RLYP. Societe Generale bought a new stake in Relypsa during the second quarter worth $133,000. Laurion Capital Management LP bought a new stake in Relypsa during the second quarter worth $185,000. Stifel Financial Corp bought a new stake in Relypsa during the second quarter worth $190,000. Janney Montgomery Scott LLC bought a new stake in Relypsa during the second quarter worth $262,000. Finally, BlackRock Advisors LLC boosted its stake in Relypsa by 10.8% in the second quarter. BlackRock Advisors LLC now owns 16,477 shares of the company’s stock worth $305,000 after buying an additional 1,604 shares during the last quarter.

Relypsa Company Profile

Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.

5 Day Chart for NASDAQ:RLYP

Receive News & Stock Ratings for Relypsa Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc. and related stocks with our FREE daily email newsletter.